Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3163 Comparison of whole-body MRI and 68Ga-DOTATATE PET-CT findings in patients with suspected peritoneal metastases from neuroendocrine tumors

Introduction:

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Engbersen M

Authors: Engbersen M, Versleijen M, Lambregts D, Beets-Tan R, Tesselaar M,

Keywords: 68Ga-DOTATATE PET/CT, MRI, PET/CT, diffusion-weighted MRI, metastatic NET,

#2119 Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)

Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burge M,

Keywords: 68Ga-DOTATATE PET-CT, SUV parameters, Tumor response, Somatostatin receptor tumor volume,

#2066 Pretherapeutic Predictors of Tumor Absorbed Dosimetry in Radionuclide Therapy for Metastatic Neuroendocrine Tumors

Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate Positron Emission Tomography (68Ga-DOTATATE PET) standardised uptake value (SUV) has shown conflicting results in the prediction of tumour lesion absorbed dosimetry (TLAD).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Ladwa R, Pattison D, Smith J, Goodman S, Burg M,

Keywords: 68Ga-DOTATATE PET-CT, Tumor Dosimetry, SUV predictors,

#287 Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Carroll R, Tan T, Todd J, Al-Nahhas A, Bomanji J,

Keywords: 177Lutetium-DOTATATE therapy, neuroendocrine tumor, paraganglioma, SDHB,